Dark

Check out our Level2View

AMAM
Ambrx Biopharma, Inc. Common Stock
stock NASDAQ

Inactive

Mar 6, 2024

28.00USD+0.071%(+0.02)1,439,663

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 9, 2021

09:50PM EST Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low Benzinga

09:48PM EST Ambrx Biopharma Inc. Presents Data From Ongoing ACE-Breast-01 Phase 1 Clinical Study Of ARX788 At San Antonio Breast Cancer Symposium; Co. Reports 'ARX788 demonstrated robust anti-tumor activity, with disease control rate of 100% in the 29 patients' Benzinga

09:46PM EST The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO Benzinga

09:08AM EST Ambrx Biopharma Presents Positive Data From Ongoing ACE-Breast-01 Phase 1 Clinical Study Of ARX788 RTTNews

09:00AM EST Ambrx Biopharma Inc. Presents Positive Data from Ongoing ACE-Breast-01 Phase 1 Clinical Study of ARX788 at San Antonio Breast Cancer Symposium Business Wire

Dec 8, 2021

08:19AM EST The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom Benzinga

Dec 6, 2021

06:07AM EST The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More Benzinga

Nov 19, 2021

04:05PM EST Ambrx Biopharma Inc. Announces Acceptance of Two Poster Presentations at the 2021 San Antonio Breast Cancer Symposium Business Wire

Nov 4, 2021

08:53AM EDT Ambrx Biopharma Inc. Announces First Patient Dosed In Its Global Phase 2 ACE-Breast-03 Clinical Study Of ARX788 For The Treatment Of HER2-Positive Metastatic Breast Cancer Benzinga

Nov 1, 2021

04:05PM EDT Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference Business Wire

Oct 28, 2021

04:25PM EDT Ambrx Biopharma Reports H1 Sales $5.1M, Down from $6.5M YoY Benzinga

04:05PM EDT Ambrx Biopharma Inc. Reports 1H 2021 Financial Results and Provides Corporate Update Business Wire

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 5, 2021

08:37AM EDT Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment Benzinga

Oct 4, 2021

08:28AM EDT Ambrx Announces Positive Data On ARX788 For The Treatment Of HER2+ Gastric Cancer Presented At CSCO Benzinga

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 9, 2021

04:30PM EDT Ambrx to Participate in Panel Discussion at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Aug 3, 2021

08:17AM EDT Ambrx Says First Patient Dosed In Phase 1 Trial For ARX517, ADC In Development To Treat PSMA Expressing Tumors RTTNews

08:06AM EDT Ambrx Announces First Patient Dosed In A Phase 1 Trial For ARX517, An ADC In Development To Treat PSMA Expressing Tumors Benzinga

Jul 13, 2021

05:20PM EDT These 3 New Biotechs Have Differentiated Platforms, Technology: BofA Benzinga

10:13AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 Benzinga

06:21AM EDT Goldman Sachs Initiates Coverage On Ambrx Biopharma with Buy Rating, Announces Price Target of $53 Benzinga

06:18AM EDT B of A Securities Initiates Coverage On Ambrx Biopharma with Buy Rating, Announces Price Target of $26 Benzinga

06:14AM EDT Cowen & Co. Initiates Coverage On Ambrx Biopharma with Outperform Rating Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 30, 2021

08:04AM EDT Ambrx Appoints Sonja Nelson As CFO RTTNews

08:00AM EDT Ambrx Appoints Sonja Nelson as Chief Financial Officer Business Wire

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 18, 2021

11:00AM EDT Ambrx Biopharma Shares Open For Trade At $18; IPO Priced At $18/Share Benzinga

09:30AM EDT Ambrx Biopharma Shares Expected To Open For Trade Today; IPO Priced At $18/Share Benzinga

Jun 17, 2021

11:21PM EDT Ambrx Prices IPO Of 7 Mln ADSs At $18/ADS RTTNews

11:15PM EDT Ambrx Announces Pricing of Initial Public Offering Business Wire

Share